PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Medigene AG

24.03.2004 – 08:35

Medigene AG

euro adhoc: MediGene AG
Restructuring & Recapitalisations / MediGene Successfully Closes Capital Increase by 16.7 Million EUR As Announced (E)

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Martinsried - San Diego, March 24, 2004. After successful closure of
the first step of the three-step capital increase measures announced
on March 4, 2004, the German-American biotech company MediGene AG
(Frankfurt, Prime Standard: MDG) has also successfully placed the
second and the third step. The approximately 1.1 million new shares
from the second capital increase, offered to the company's current
shareholders at a subscription price of 6.80 EUR each, as well as the
total of 1.5 million convertible bonds also offered to the
shareholders at a price of 1.00 EUR each, have been fully placed with
shareholders as well as institutional investors. Proceeds from the
issue of new shares and convertible bonds, including the preceding
first step of the capital increase, amount to 16.7 million EUR, thus
raising the company's current cash available to almost 40 million
EUR.
end of announcement        euro adhoc 24.03.2004

Further inquiry note:

Julia Hofmann
Tel.: +49 (0)89 8565 3324
E-mail: j.kern@medigene.com

Branche: Biotechnology
ISIN: DE0005020903
WKN: 502090
Index: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Niedersächsische Börse zu Hannover / free trade
Berliner Wertpapierbörse / free trade
Bayerische Börse / free trade
Hamburger Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade

Original content of: Medigene AG, transmitted by news aktuell